RT Journal Article
SR Electronic
T1 Point-of-care lung ultrasonography for early identification of mild COVID-19: a prospective cohort of outpatients in a Swiss screening center
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.23.21254150
DO 10.1101/2021.03.23.21254150
A1 Schaad, Siméon
A1 Brahier, Thomas
A1 Hartley, Mary-Anne
A1 Cordonnier, Jean-Baptiste
A1 Bosso, Luca
A1 Espejo, Tanguy
A1 Pantet, Olivier
A1 Hugli, Olivier
A1 Carron, Pierre-Nicolas
A1 Meuwly, Jean-Yves
A1 Boillat-Blanco, Noémie
YR 2021
UL http://medrxiv.org/content/early/2021/03/26/2021.03.23.21254150.abstract
AB Background Early identification of SARS-CoV-2 infection is important to guide quarantine and reduce transmission. This study evaluates the diagnostic performance of lung ultrasound (LUS), an affordable, consumable-free point-of-care tool, for COVID-19 screening.Methods This prospective observational cohort included adults presenting with cough and/or dyspnea at a SARS-CoV-2 screening center of Lausanne University Hospital between March 31st and May 8th, 2020. Investigators recorded standardized LUS images and videos in 10 lung zones per subject. Two blinded independent experts reviewed LUS recording and classified abnormal findings according to pre-specified criteria to investigate their predictive value to diagnose SARS-CoV-2 infection according to PCR on nasopharyngeal swabs (COVIDpos vs COVIDneg). We finally combined LUS and clinical findings to derive a multivariate logistic regression diagnostic score.Results Of 134 included patients, 23% (n=30/134) were COVIDpos and 77% (n=103/134) were COVIDneg; 85%, (n=114/134) cases were previously healthy healthcare workers presenting within 2 to 5 days of symptom onset (IQR). Abnormal LUS findings were significantly more frequent in COVIDpos compared to COVIDneg (45% versus 26%, p=0.045) and mostly consisted of focal pathologic B-lines. Combining LUS findings in a multivariate logistic regression score had an area under the receiver-operating curve of 63.9% to detect COVID-19, but improved to 84.5% with the addition of clinical featuresConclusions COVIDpos patients are significantly more likely to have lung pathology by LUS. Our findings have potential diagnostic value for COVID-19 at the point of care. Combination of clinical and LUS features showed promising results, which need confirmation in a larger study population.What is already known on the subjectLung ultrasonography (LUS) is a consumable-free, easy-to-use, portable, non-radiating and non-invasive screening tool that can be performed at the bedside: its diagnostic performance for pneumonia has been established.Recent studies conducted in emergency department showed a correlation between LUS findings and COVID-19 diagnosis.What the study adsThis is the first study assessing the diagnostic performance of LUS for COVID-19 in outpatients with mild acute respiratory tract infection.Mild COVID-19 patients are more likely to have lung pathology by LUS compared with COVID-19 negative.Combination of clinical and LUS features showed promising results with a potential diagnostic value for COVID-19 at the point of care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by an academic award of the Leenaards Foundation (to NBB), by the Foundation of Lausanne University Hospital, and the Emergency Department Lausanne University Hospital. The funding bodies had no role in the design of the study and collection, analysis and interpretation of data and in writing the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Swiss Ethics Committee of the canton of Vaud (CER-VD 2019-02283).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data files are available at https://zenodo.org/record/4617904#.YFmlHi3pNQI https://zenodo.org/record/4617904#.YFmlHi3pNQI